<DOC>
	<DOC>NCT00425854</DOC>
	<brief_summary>The purpose of this trial is to evaluate the efficacy, safety and pharmacokinetics of BIBW 2992, a dual, irreversible EGFR- and HER2-inhibitor, in two cohorts of patients with HER2-negative breast cancer after failure of no more than three regimen of prior chemotherapy.</brief_summary>
	<brief_title>An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion criteria: Female patients age 18 years or older Histologically proven breast cancer after failure or relapse of no more than three lines of chemotherapy including adjuvant, irrespective of prior hormone therapy metastatic disease (stage IV); HER2negative patients (HER2 1+ or negative, or HER2 2+ and FISH negative) At least one measurable tumour lesion (RECIST); Availability of tumour samples Written informed consent that is consistent with ICHGCP guidelines and local law Eastern Cooperative Oncology Group (ECOG, R010787) performance score 0 2. Exclusion criteria: Active infectious disease Gastrointestinal disorders that may interfere with the absorption of the study drug or chronic diarrhoea Serious illness, concomitant nononcological disease or mental problems considered by the investigator to be incompatible with the protocol Active/symptomatic brain metastases Cardiac left ventricular function with resting ejection fraction &lt; 50% (below upper limit of normal) ANC less than 1500/mm3 platelet count less than 100 000/mm3 Bilirubin greater than 1.5 mg /dl (&gt;26 and#61549 mol /L, SI unit equivalent) AST and ALT greater than 2.5 times the upper limit of normal or greater 5 times the upper limit of normal in case of known liver metastases Serum creatinine greater than 1.5 mg/dl (&gt;132 and#61549 mol/L, SI unit equivalent) Patients who are sexually active and unwilling to use a medically acceptable method of contraception Pregnancy or breastfeeding Concomitant treatment with other investigational drugs or other anticancertherapy during this study and/or during the past two/four weeks, prior to the first treatment with the trial drug. Concurrent treatment with biphosphonates is allowed Previous treatment with trastuzumab, EGFR, or EGFR/HER2inhibitors patients unable to comply with the protocol Active alcohol or drug abuse Other malignancy within the past 5 years</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>